echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Positive results from pivotal clinical trials of Biohaven and Pfizer's oral CGRP receptor antagonists

    Positive results from pivotal clinical trials of Biohaven and Pfizer's oral CGRP receptor antagonists

    • Last Update: 2022-05-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 14, 2022, Biohaven Pharmaceutical and Pfizer announced positive top-line results from a Phase 3 clinical trial of rimegepant in adults with acute migraine


    Migraine is a very common chronic disease


    This is the fourth Phase 3 clinical trial of rimegepant for the acute treatment of migraine, and the first in the Asia-Pacific region, led by BioShin, a wholly-owned subsidiary of Biohaven in the Asia-Pacific region


    References:

    [1] Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea.


    (Original abridged)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.